Your Colonoscopy Prep May Disrupt Gut Bacteria for Weeks
A Phase 4 trial examines how two common bowel prep laxatives reshape the gut microbiome and how quickly it recovers.
Summary
Before a colonoscopy, patients must clear their colon using strong laxatives — but this process doesn't just remove waste. It also flushes out billions of beneficial gut bacteria. This completed Phase 4 trial compared two common bowel prep agents — polyethylene glycol (PEG) electrolyte dispersions and sodium picosulfate — in patients with colon polyps, tracking how each laxative altered gut microbiome composition and how quickly bacterial communities recovered afterward. The findings matter because gut microbiome disruption has been linked to inflammation, immune changes, and metabolic effects. Understanding which prep agent causes less microbiome damage — and supports faster recovery — could help clinicians make better choices for patients, especially those with existing gut health concerns or who require repeat colonoscopies.
Detailed Summary
Bowel preparation before colonoscopy is a routine medical necessity, but its impact on the gut microbiome has received surprisingly little systematic attention. The gut microbiome — the vast community of bacteria, fungi, and other microorganisms residing in the colon — plays a critical role in immunity, metabolism, and even brain health. Disrupting it, even temporarily, may have consequences that extend beyond the procedure itself.
This completed Phase 4 clinical trial, sponsored by Zhang Yanli, set out to investigate exactly that. Researchers enrolled patients with colonic polyps who were undergoing endoscopic polypectomy — a procedure requiring thorough bowel preparation. Participants were assigned to one of two common laxative regimens: compounded polyethylene glycol (PEG) electrolyte dispersions or compounded sodium picosulfate. The study tracked changes in gut microbiome composition before preparation, immediately after, and at recovery time points.
The central questions were whether the two agents produced meaningfully different microbiome disruption, how bacterial diversity and specific species abundances shifted, and how long full or partial recovery took. PEG-based preps and stimulant laxatives like sodium picosulfate work through different mechanisms — osmotic versus secretory — and may therefore affect the microbiome differently.
Full results from this trial are not yet publicly detailed in the abstract, but its completion signals that data exist on the comparative microbiome impact of these two agent classes. Given the millions of colonoscopies performed annually worldwide, even modest differences in microbiome recovery profiles could influence clinical protocols — particularly for immunocompromised patients, those with inflammatory bowel conditions, or individuals requiring frequent surveillance colonoscopies.
Caveats include the narrow patient population (colon polyp patients only), limited abstract detail, and the single-center sponsorship, which may limit generalizability. Nevertheless, this trial addresses a clinically underappreciated question at the intersection of gastroenterology and microbiome science.
Key Findings
- Two common bowel prep agents — PEG and sodium picosulfate — were compared for their distinct effects on gut microbiome composition.
- The trial tracked microbiome recovery over time after prep, addressing how long disruption persists post-colonoscopy.
- Patients studied had colon polyps, a population at elevated colorectal risk who may undergo repeat procedures.
- Phase 4 designation indicates this studied real-world clinical use of already-approved laxative preparations.
- Findings could guide clinicians toward prep agents causing least microbiome disruption, especially for vulnerable patients.
Methodology
This was a completed Phase 4 clinical trial comparing two active laxative interventions — polyethylene glycol electrolyte dispersions and sodium picosulfate — in patients with colonic polyps undergoing bowel preparation prior to endoscopic polypectomy. The study design focused on longitudinal gut microbiome sampling to capture composition changes and recovery trajectories. Specific sample sizes, randomization details, and follow-up durations were not disclosed in the available abstract.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data are not publicly available; key outcomes, effect sizes, and statistical results are unknown. The patient population is limited to those with colon polyps, which may not represent the broader colonoscopy population. Single-sponsor status and lack of multi-center design details raise questions about generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: